Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Age-related macular degeneration (AMD) is the leading cause of vision loss for people over 65. We have excellent treatments for the wet form of AMD. But until recently, we haven’t had any ...

For instance, your visual acuity according to the eye chart may seem really good, yet you still read really slowly or have trouble spotting uneven pavement when you walk down the street.

(NASDAQ: NASDAQ:OCUL), a biopharmaceutical company valued at $1.28 billion, has made significant strides in its clinical trials for AXPAXLI™, a treatment for wet age-related macular degeneration ...

Treatment of hypertensive retinopathy begins with controlling hypertension. Some of the complications can be treated by an ophthalmologist with injectable medications into the eye as well as laser ...

GA, a form of advanced dry age-related macular degeneration, impacts around one million people in the U.S. Both conditions can lead to severe vision loss and progressive deterioration. Scott ...

to develop innovative treatments for patients with age-related macular degeneration (AMD). This relationship, initiated in 2024, represents a major step forward by bringing together Bausch + Lomb ...

The Brooklyn-based startup is specifically targeting people with macular degeneration. The degenerative eye disease affects roughly 13% of U.S. residents aged 40 and up, according to figures from ...